113 related articles for article (PubMed ID: 8973600)
21. p53 heterozygosity results in an increased 2-acetylaminofluorene-induced urinary bladder but not liver tumor response in DNA repair-deficient Xpa mice.
Hoogervorst EM; van Oostrom CT; Beems RB; van Benthem J; Gielis S; Vermeulen JP; Wester PW; Vos JG; de Vries A; van Steeg H
Cancer Res; 2004 Aug; 64(15):5118-26. PubMed ID: 15289314
[TBL] [Abstract][Full Text] [Related]
22. Regulation of DNA repair gene expression in human cancer cell lines.
McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
24. UV-induced skin carcinogenesis in xeroderma pigmentosum group A (XPA) gene-knockout mice with nucleotide excision repair-deficiency.
Tanaka K; Kamiuchi S; Ren Y; Yonemasu R; Ichikawa M; Murai H; Yoshino M; Takeuchi S; Saijo M; Nakatsu Y; Miyauchi-Hashimoto H; Horio T
Mutat Res; 2001 Jun; 477(1-2):31-40. PubMed ID: 11376684
[TBL] [Abstract][Full Text] [Related]
25. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines.
Weaver DA; Crawford EL; Warner KA; Elkhairi F; Khuder SA; Willey JC
Mol Cancer; 2005 May; 4(1):18. PubMed ID: 15882455
[TBL] [Abstract][Full Text] [Related]
26. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
Jiang H; Yang LY
Cancer Res; 1999 Sep; 59(18):4529-34. PubMed ID: 10493501
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.
Hector S; Nava ME; Clark K; Murphy M; Pendyala L
Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375
[TBL] [Abstract][Full Text] [Related]
28. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182
[TBL] [Abstract][Full Text] [Related]
29. EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene.
Huang Y; Wang X; Niu X; Wang X; Jiang R; Xu T; Liu Y; Liang L; Ou X; Xing X; Li W; Hu C
Mol Carcinog; 2017 Feb; 56(2):447-463. PubMed ID: 27253463
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin transiently up-regulates hHR23 expression through enhanced translational efficiency in A549 adenocarcinoma cells.
Shen YH; Chen BR; Cherng SH; Chueh PJ; Tan X; Lin YW; Lin JC; Chuang SM
Toxicol Lett; 2011 Sep; 205(3):341-50. PubMed ID: 21742020
[TBL] [Abstract][Full Text] [Related]
31. XPA protein as a limiting factor for nucleotide excision repair and UV sensitivity in human cells.
Köberle B; Roginskaya V; Wood RD
DNA Repair (Amst); 2006 May; 5(5):641-8. PubMed ID: 16413230
[TBL] [Abstract][Full Text] [Related]
32. Mutation analysis of the human homologue of Drosophila patched and the xeroderma pigmentosum complementation group A genes in squamous cell carcinomas of the skin.
Eklund LK; Lindström E; Undén AB; Lundh-Rozell B; Ståhle-Bäckdahl M; Zaphiropoulos PG; Toftgård R; Söderkvist P
Mol Carcinog; 1998 Feb; 21(2):87-92. PubMed ID: 9496908
[TBL] [Abstract][Full Text] [Related]
33. p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene.
Ide F; Kitada M; Sakashita H; Kusama K; Tanaka K; Ishikawa T
Am J Pathol; 2003 Nov; 163(5):1729-33. PubMed ID: 14578172
[TBL] [Abstract][Full Text] [Related]
34. 14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.
Lai KK; Chan KT; Choi MY; Wang HK; Fung EY; Lam HY; Tan W; Tung LN; Tong DK; Sun RW; Lee NP; Law S
Tumour Biol; 2016 Feb; 37(2):2127-36. PubMed ID: 26346170
[TBL] [Abstract][Full Text] [Related]
35. [ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].
Bogush TA; Popova AS; Dudko EA; Bogush EA; Tyulyandina AS; Tyulyandin SA; Davydov MI
Antibiot Khimioter; 2015; 60(3-4):42-50. PubMed ID: 26415382
[TBL] [Abstract][Full Text] [Related]
36. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
37. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models.
van Steeg H; de Vries A; van Oostrom CTh ; van Benthem J; Beems RB; van Kreijl CF
Toxicol Pathol; 2001; 29 Suppl():109-16. PubMed ID: 11695546
[TBL] [Abstract][Full Text] [Related]
38. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
39. [Effect of XPA expression on the chemotherapy sensitivity of A549/DDP cells].
Zhang Q; Wu JX; Wei YP; Hao JQ; Huang SY; Dong L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov; 28(11):1182-4. PubMed ID: 23127410
[TBL] [Abstract][Full Text] [Related]
40. Xeroderma pigmentosum group A gene action as a protection factor against 4-nitroquinoline 1-oxide-induced tongue carcinogenesis.
Ide F; Oda H; Nakatsuru Y; Kusama K; Sakashita H; Tanaka K; Ishikawa T
Carcinogenesis; 2001 Apr; 22(4):567-72. PubMed ID: 11285190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
